DH
Therapeutic Areas
Sutro Biopharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Luveltamab tazevibulin (luvelta) | Follicular Lymphoma (3L+) | Phase 2/3 |
| STRO-003 | Solid Tumors | Preclinical |
| CC-99712 (BCMA ADC) | Multiple Myeloma | Phase 1 |
| M1231 (EGFR/MUC1 bispecific ADC) | Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma | Phase 1 |
Leadership Team at Sutro Biopharma
JC
Jane Chung
Chief Executive Officer
DP
David Pauling
Chief Administrative Officer and General Counsel
GC
Greg Chow
Chief Financial Officer
DL
Devendra Luhar
Senior Vice President, Technical Operations
HG
Hans-Peter Gerber
Chief Scientific Officer
KL
Kari Leetch
Senior Vice President, Head of People and Culture
CM
Connie Matsui
Chair, Board of Directors
HH
Heidi Hunter
Member, Board of Directors
JP
James Panek
Member, Board of Directors
SJ
Sukhi Jagpal
Member, Board of Directors